Official statement from Randox on Covid-19 testing

Home - Archives for Randox Communications

Official statement from Randox on Covid-19 testing

News       About Us        Randox Biochip

 

03 April 2020

 

OFFICIAL STATEMENT FROM RANDOX

On the emergence of the Covid-19 threat Randox utilised their years of regulated diagnostic experience to quickly develop and robustly validate a test for the Covid-19 virus.  Randox had significant confidence in this test and presented them to Public Health England (PHE) for evaluation.  PHE were managing this validation process for each of England, Wales, Scotland and Northern Ireland.

The UK Government showed significant confidence in Randox’s capability and conducted full engagement and planning subject to PHE acceptance of the Randox test.  When PHE acceptance was granted, the Randox part in the national plan had been prepared and was quickly initiated.

We understand that the national plan for the testing of key workers is exactly that, a national plan, inclusive of Northern Ireland.  Initially relatively small numbers of tests were sent to the areas of significant national threat in London.

The planning for the national distribution of test kits is being managed by the various relevant statutory agencies however Randox has made the case that tests should be made available locally.  Following that engagement, tests have now been made directly available within Northern Ireland and Randox will continue to support Northern Ireland within the UK national plan.

Randox have acted with speed and initiative throughout this crisis and will continue to ramp up our testing capability to support the national testing plan for key workers in Northern Ireland.

Every part of Randox’s business is focused on doing everything we can to support the Covid-19 testing programme, to both save lives and ensure the speediest possible return to a more normal society.

For more information please contact the Randox PR team by emailing randoxpr@randox.com

 

QNOSTICS

QCMD

BIOSCIENCES


Randox joins government drive on COVID-19 tests for frontline NHS staff

News       About Us        Randox Biochip

 

27 March 2020

 

Randox Laboratories is partnering with the government to develop a new coronavirus testing programme in which NHS staff will be first in line.

The new service, which will be free, will help to end the uncertainty of whether NHS staff need to stay at home. Those who test negative for coronavirus will be able to return to work – enhancing the capacity of the NHS and social care to treat patients and care for those in community settings, with plans for a full roll-out for health, social care and other frontline workers.

Randox are providing high volume home sample collection kits and laboratory testing, based on two simultaneous tests on the proprietary Randox Biochip.

Randox CEO Dr Peter FitzGerald, said:

“We have an excellent Covid-19 assay and we are committed to supporting the government and this important initiative to test key workers and support vital public services.

“Randox Laboratories is now operational for COVID-19 testing and will be ramping up extensively in the coming weeks. This will provide extensive employment opportunities for laboratory and support staff.

“Our first tests have gone to the London Ambulance Service and we look forward to playing our role in ensuring that this critical capability continues to operate.”

To offer its coronavirus testing capabilities to the new programme, Randox’s Coronavirus Multiplex Array recently underwent evaluation from Public Health England.

In its evaluation of the Randox test, Public Health England’s report noted that the assay correctly identified all positive and negative samples without exception.

As a result the government are proceeding to utilise the Randox Coronavirus Multiplex Array in the new testing programme for NHS staff, with an exceptionally high degree of confidence.

Health Secretary Matt Hancock said:

“We want to save lives, protect the most vulnerable, and relieve pressure on our NHS.

“Healthcare staff are key in our fight against the virus and I want to ensure that any frontline NHS or care worker who has symptoms of coronavirus or who has a family member with symptoms can be tested quickly and reliably.

“I pay tribute to the generosity and public spirit of Britain’s universities, research institutes and companies who have lent us their equipment without hesitation.”

Dr Jenny Harries, Deputy Chief Medical Officer, said:

“Laboratory-based testing on this scale is a little like building the medical equivalent of a car factory. We are assembling many different parts, some of them quite specialised and hard to find, then getting them to work accurately together in a highly co-ordinated process. There are bound to be teething problems, so we cannot switch on hundreds of thousands of lab tests overnight. But we hope that soon these hub laboratories will be operating round the clock, allowing us to significantly scale up our testing.”

For more information or to arrange interviews, please contact the Randox PR team by emailing randoxpr@randox.com

QNOSTICS

QCMD

BIOSCIENCES


Point of care coronavirus test from Randox and Bosch will launch in April 2020

News       About Us        Randox Biosciences

26 March 2020

 

Vivalytic Viral Respiratory Tract Infection Array Detecting SARS-CoV-2 (COVID-19)

A game-changing point of care coronavirus test from global diagnostics company Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions will launch in April 2020.

The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

This provides a more comprehensive respiratory screening which enables precise and informed treatment decisions to be made.

Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences, commented;

“This array focuses not only on the identification of the novel coronavirus strain that causes COVID-19, but also nine other respiratory infection targets simultaneously, including Influenza A and B, Sarbecovirus and MERS. The aim is to diagnose patients fast and accurately from a single genetic sample, maximising containment of the virus whilst minimising the spread. With the development of this array onto a fully automated platform, patients can be diagnosed rapidly at point of care locations globally such as pharmacies and doctor surgeries.”

The Viral Respiratory Tract Infection Array is one of the world’s first multiplex molecular diagnostic tests meeting the COVID-19 testing recommendations of the World Health Organisation (WHO) and the Centres for Disease Control (CDC).

The target genes for COVID-19 being used on the VRI array represent conserved regions of the genome which have been chosen for their high sensitivity and specificity.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

“We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

The new VRI test will be conducted on Vivalytic a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimises the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilises end point PCR.  The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user to run the patient sample.

 

Key Benefits of Vivalytic | Point of Care Platform

  • Fully-automated
  • User friendly
  • No laboratory training required
  • 4 step work flow
  • Minimal contamination risk – fully contained system
  • No peripherals required – hygienic
  • Touchscreen
  • Connects to LIMS (Laboratory Information Management System)
  • Sample Type: Nasopharyngeal Swab
  • Sample Volume: 300µl clinical sample

For more information or to arrange interviews, please contact info@randoxbiosciences.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Drug Use in Australia: A Randox Toxicology Report

News       About Us        Randox Toxicology

19 March 2020

 

 

 

Drug Use in Australia

 

 

Drug Use in Australia: A Randox Toxicology Report

Approximately 43% of all Australians aged 14 years and over have admitted to using an illicit drug on at least one occasion throughout their life.

Additionally, nearly 16% of Australians have confessed to using an illicit drug at least once in the last year.

Cannabis is the most frequent drug used among the Australian people with an estimate of 35% lifetime use. The closest to this is MDMA which has an estimate of around 11% lifetime use.

A reason towards the high cannabis use may be due to the Australian Capital Territory legalizing the recreational possession and cultivation of marijuana in September 2019. This now allows any residents of the capital territory over the age of 18 to possess up to 50 grams of dried marijuana and grow two plants per person or four per household at a time. The supply of the drug to other people however still remains an illegal act.

It is estimated that approximately 60 per cent of those who use illicit drugs are also daily smokers and/or consume alcohol at a level that is considered to be of risk to their everyday health. Another noticeable finding among drug users in Australia is that the majority of methamphetamine, cocaine or ecstasy users are also users of other illicit drugs.

Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes.

To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

Randox Toxicology Products and Services

BIOCHIP

EVIDENCE

ELISA

MATRICES

Want to know more about Randox?

Contact us or visit our homepage to view more.


We Are Randox | Tech Trailblazer Margaret Le Roux

randox-careers

About Us       News        Contact

18 March 2020

Tech Trailblazers: Margaret Le Roux

Tech Trailblazers: Margaret Le Roux

Sync NI, in celebration of Women in Tech, recently spoke with our IT Operations Team Leader Margaret.

Read on as Margaret share’s her typical day, the favourite thing about her job, and how her specialist role at Randox combines a degree in Biomedical Science with a passion for software development.

Name: Margaret Le Roux

Role: IT Operations Team Leader, Randox Laboratories

Biography:

I graduated from the University of Rhodesia (now known as Zimbabwe), as a Biomedical Scientist in 1980. My career in South Africa was then predominantly in the clinical laboratory medicine field, and I qualified as a Technical Assessor for clinical laboratories through the South African National Accreditation System. I moved to Belfast in 2014 and started work with Randox.

What does your typical day look like?

I work in an IT Operations role bridging our science and quality control software, which assesses the accuracy and reliability of blood tests, and the machines they are run on, in the likes of hospitals, laboratories, and veterinary clinics. On a typical day, I deal with customer queries about this software, troubleshoot the issues, and drive new developments to improve our systems and applications. I also spend time training Randox staff, mentoring some of my junior colleagues, and speaking at Biomedical Science Conferences to educate others in the industry about the importance of quality control software.

What are you currently working on?

I’m currently working on the specification for our external quality assessment software, which involves a mock blood sample being run in a laboratory’s analyser, and the result being sent back to Randox so that we can independently check that it is performing correctly.

I have also been working on the software project that saw Randox win ‘Project Team of the Year’ at the 2019 Belfast Telegraph IT Awards. This cloud-based quality control technology was specifically designed for ‘Point of Care’ machines which provide finger prick blood tests for conditions like heart disease and diabetes, in pharmacies, GP surgeries and A&E departments.

Did you always want to work in the tech industry?

I have been very lucky that my specialist role at Randox combines my degree in Biomedical Science, and my experience in QC, with my passion for software development. In South Africa, I worked as a Quality Officer for a large private laboratory, with 3 main laboratories and over 100 peripheral sites across 10 African countries. The management of quality control data was a huge job and as such I became interested in a software program that could assist the lab with this task.

What inspired you to join Randox in particular?

Whilst working in South Africa, I was one of Randox’s customers, and made extensive use of their quality control products. Randox has always had a very good reputation in South Africa so when I moved to Belfast it was a natural choice for me.

What’s your favourite part about your work?

It’s a great feeling when we introduce a new release to our software and you know that the customers are going to benefit from it.

What would you say to other people considering a job in the tech industry?

A job in the tech industry is simultaneously exciting and challenging, as each day brings something new. You will continually be making improvements and striving to make something better, which is a good work ethic. It’s really satisfying when you are part of a team which develops a software program that is so well accepted in the market and useful to the customer.

How do you see this technology impacting on our lives?

The technology industry is so fluid and moving at such a fast pace, and there are developments across all industries which are making our lives easier. At Randox in particular, our software is helping a range of healthcare professionals – whether laboratory technicians, clinicians or veterinarians – to achieve our shared goal of saving and improving the lives of patients. It’s rewarding to know we are making a difference.

Who inspired you to work in this field?

In the field of Quality Control, I was inspired by Dr Pandelani Rambau, a Clinical Pathologist from Johannesburg. In IT, it was a colleague Sean Dicks who showed me that there is always a way to get a program to do what you need it to do.

What do you consider to be the most important tech innovation or development in recent years?

The development of communication devices has been incredibly important. They open up the whole world to us and we can access things, both socially and for education, that previously were only available to a few. They have brought so much information to our fingertips.

What tech gadget could you not live without?

I couldn’t live without my phone, because it is so much more than just a phone. It holds all the important things that make up my life, like messages, memories, and my calendar.

To find out more about Randox IT and the vacancies we have in the team, please email recruitment@randox.com 

For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.

Want to know more?

Contact us or visit our Randox Careers

Find out more about Randox Careers

Careers News

Vacancies

Our People

Careers Website


RTS Blog | Wales introduce minimum alcohol pricing

12 March 2020

Wales introduce minimum alcohol pricing

 

RTS Blog | Wales introduce minimum alcohol pricing

From 2nd March, there was a change in the way alcohol is sold in Wales, with the introduction of minimum unit pricing (MUP).

Retailers and any outlets serving alcohol must charge at least 50p a unit, meaning a typical bottle of wine costs no less than £4.69. Welsh Health Minister Vaughan Gething said it would tackle “harmful and damaging” drinking of cheap, strong alcohol.

A recent report found that alcohol sales in Scotland had dropped after a similar system was implemented in May 2018. The Public Health Minimum Price for Alcohol Wales Act 2018 forces retailers to use a formula for working out minimum pricing.

What is a unit of alcohol?

  • A unit is 10ml of pure alcohol
  • This is equivalent to about half a pint of lower or standard-strength beer or cider
  • A single 25ml shot of sprits is about one unit
  • A small 125ml glass of wine contains about 1.5 units

Source: NHS Direct Wales

What is minimum unit pricing?

Minimum unit pricing (MUP) is a method in setting a baseline price below which no one can sell an alcoholic drink. The price is based on how much alcohol is in each drink. The minimum price that’s being set in Wales is 50p per unit of alcohol. Whether the drink is beer, cider, wine, spirits or any other kind of alcoholic drink; its minimum price will depend on how much alcohol it contains. For example:

  • A standard-strength pint of beer or cider contains around 2.5 units of alcohol, so it can’t be sold in Wales for less than £1.25 (2.5 x 50p)
  • A bottle of wine has about 10 units of alcohol in it, so the minimum price for it is around £5 (10 x 50p)
  • A bottle of whisky or vodka contains around 26 units, and so cannot be sold for less than £13 (26 x 50p)

Why has it been introduced?

Official figures show about 500 people die in Wales each year from alcohol-related causes, with 60,000 hospital admissions related to alcohol consumption, adding up to an estimated £159m cost to the Welsh NHS r.

Dr Sarah Aitken, director of public health for Aneurin Bevan University Health Board, said the organisation had been supportive of the law change since it was first mooted.

“We see the effects of excessive alcohol consumption on people’s health every day,” she said.

 About Randox Testing Services

Randox Testing Services are a specialist in the workplace drug & alcohol testing industry. We provide testing solutions for companies who want to reduce the impact of substance misuse in their workplace. With a range of service options and expert staff on hand to provide help and training to staff, our services will help to eradicate the impacts of drugs and alcohol.

To find out more about our range of products and how our service packages can help your company, contact us today.

Email – testingservices@randox.com

Phone – +44 (0) 28 9445 1011

 

Want to know more?

Contact us or visit our website to read more.


World-first milk test for cattle herd health developed by Randox scientists

randox-food-diagnostics

About RFD        News        Contact Us

04 March 2020

World-first milk test for cattle herd health developed by Randox scientists

Randox scientists have today revealed a revolutionary new method for Bovine disease testing which will radicalise cattle screening against some of the world’s most prevalent bovine viruses, bacteria and parasites.

Named the Bovine Pathogen Array, the test is designed to facilitate prompt diagnosis and the identification of co-infection, which aids in the reduction of the spread of disease, limits the need for medical intervention and milk withdrawal periods, and also ensures maximum efficiency at the producer level.

The veterinary multiplex IVD immunoassay from global diagnostics company Randox, headquartered in Northern Ireland, is the first of its kind on the market – detecting antibodies against six pathogens simultaneously from a single milk sample, rather than the standard more time-consuming method of singleplex ELISA testing currently required for each individual disease.

David Ferguson, Managing Director, Randox Food Diagnostics, commented;

“Our Bovine Pathogen Array is the first of its kind in the world and has the potential to revolutionise how cattle are diagnosed and how quickly pathogens are spread amongst a herd. Simultaneous detection of the rifest, and most problematic, bovine viruses, bacteria and parasites has not been attempted before, and currently, six to seven separate ELISA tests must be conducted in order to obtain the same results as those delivered by the Bovine Pathogen Array. 

“Bringing this product to market has been a priority at Randox Food Diagnostics and we are sure that arming industry professionals with quicker and more accurate diagnostic tools will lead to increased yields, increased profit margins for producers and, ultimately, better bovine health.” 

The new Bovine Pathogen test, which is conducted on a unique piece of testing technology called the Biochip, generates results in approximately 2.5 hours, allowing faster diagnosis and identification of infected cattle. Milk samples are collected from the herd, added to a Biochip, and then placed in the corresponding analyser (called the Evidence Investigator) which runs tests for multiple diseases – Bovine Viral Diarrhoea (BVD), Infectious Bovine Rhinotracheitis (IBR), Paratuberculosis (Johne’s Disease), Leptospirosis, Neospora Caninum and Fasciola Hepatica (Liver Fluke) – all at once.

Highly contagious and, in many cases, untreatable, there has been much concern regarding outbreaks of these dangerous pathogens in the past number of years. With a global economic impact, high mortality rates, increased premature culling, decreased reproductive performance and reduced milk yield as direct losses, vital research has been long awaited in order to tackle these dangerous conditions faster and more effectively.

David continued;

“The Randox Bovine Pathogen Array contains a range of well-established antigens complemented by additional select novel analytes for BVD and Neospora Caninum. It can also differentiate between IBR vaccinated and naturally infected animals (DIVA capacity) when used in conjunction with selected vaccines. This comprehensive test menu will significantly contribute to advances in disease research and add to scientific knowledge already available with regards to coinfection, surveillance, vaccine performance and risk factors associated with disease outbreaks.

“We are proud to be able to provide reassurance for dairy producers, enabling them to get to the root of the issue before contamination occurs across the herd.”

The new Bovine Pathogen Array was recognised as most innovative assay at the recent IDF World Dairy Summit, receiving 1st prize in the poster competition. It is now available from Randox Food Diagnostics.

Please email enquiries@randoxfooddiagnostics.com for further information.

Want to know more?

Contact us or visit our Randox Food Diagnostics website.

Related Products

Meat & Seafood

Milk

Honey

Wine


Multiplex STI assay for 10 sexually transmitted infections receives CE marking

News       About Us        Randox Biosciences

02 March 2020

 

Multiplex assay for 10 sexually transmitted infections receives CE marking

CE marking has been granted to one of the most comprehensive cartridge-based STI tests.

The test, developed by the UK’s largest health diagnostics company, Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology.

Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”

The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch that provides the broadest range of test options ever seen for an analyser of its size.

Harnessing the application of multiplex assays to provide greater information from a single patient sample, the Vivalytic simplifies the testing process for otherwise complex laboratory testing procedures.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

“We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

Benefits of the Randox STI assay technology on the Vivalytic system

  • Fully automated, cartridge-based molecular diagnostics.
  • Multiplex technology detects multiple STIs, including co-infections, from a single patient sample.
  • Full molecular workflow of extraction, PCR amplification and detection.
  • A hygiene and space-saving all-in-one solution that does not require additional peripherals such as laptop, keyboard, barcode scanner or filling stations.
  • Ultimate protection of data and valuable sample material thanks to integration of software with instrument that ensures a safe and reliable run.
  • Test results can be presented either in summary or in detailed raw data form.
  • Instantly available results due to easy integration with popular standard IT systems.

The assay tests simultaneously, from one patient sample, for the STIs below;

  • Chlamydia trachomatis (CT)
  • Neisseria Gonorrhoeae (NG)
  • Trichomonas vaginalis (TV)
  • Mycoplasma genitalium (MG)
  • Treponema pallidum (syphilis) (TP)
  • Herpes simplex virus 1 (HSV-1)
  • Herpes simplex virus 2 (HSV-2)
  • Haemophilus ducreyl (HD)
  • Mycoplasma hominis (MH)
  • Ureaplasma urealyticum (UU)

For further information please contact the Randox PR team on 028 9442 2413 or email randoxpr@randox.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


Hospitals in Wuhan and Guangzhou roll out new coronavirus test developed by Randox scientists

News       About Us        Randox Biochip

 

02 March 2020

 

 

Hospitals in Wuhan and Guangzhou roll out new coronavirus test developed by Randox scientists

Randox’s pioneering new test for coronavirus, which identifies COVID-19 and differentiates it from nine other respiratory infections, is to be used in Chinese hospitals.

The comprehensive test, which is being shipped this week to hospitals in Wuhan and Guangzhou, has been developed on Randox’s unique technology platform, the Biochip.  This allows for each patient to be simultaneously tested for a range of respiratory infections inclusive of all known coronaviruses.

The Coronavirus Biochip tests each single patient sample for the SARS-CoV-2 virus that causes COVID-19, as well as nine other respiratory viruses, including SARS, MERS, and Influenza A and B. This enables clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections, prioritise patients and administer appropriate and timely treatment.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Current technologies being used to diagnose COVID-19 are focused on simply detecting the presence or lack of this singular strain and therefore neglect to differentiate it from other respiratory infections. At Randox we have developed a multiplex Viral Respiratory Infection Array that tests for COVID-19 and nine other infections simultaneously, and are delighted that this new technology will be deployed in Wuhan and other cities across China.

“The Coronavirus Biochip will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, thereby empowering clinicians to make faster and better-informed decisions.”

Due to be used in hospitals in Wuhan, the epicentre of the coronavirus outbreak, as well as in The First Affiliated Hospital of Guangzhou Medical University, the new testing technology is capable of processing 324 patient samples, generating 3240 reportable results, in just 8 hours.

The panel includes two tests for COVID-19, a specific test (SARS-CoV-2) and a confirmatory test (Sarbecoviris) on the same panel, as recommended by the World Health Organisation. This avoids the need to repeat the test, and importantly, reduces the likelihood of incorrect diagnosis, ensuring appropriate containment and reducing the risk of further contamination. This faster and more comprehensive testing will ultimately support the health service in China by facilitating the efficient use of valuable healthcare resources.

Byron Wang, CEO of Beijing Promed, Randox’s partner in providing the new coronavirus test in China, commented;

“We welcome the support of the global community in assisting us combat COVID-19 at this time. Randox is a highly regarded In Vitro Diagnostic company in China and has supported our market with high quality products for many years. We look forward to supplying this test to hospitals located within the area of greatest need and believe it will make a real difference.”

Dr FitzGerald concluded;

“Randox is committed to saving and improving lives on a global scale and we know that this new COVID-19 test will make a significant contribution to the global coronavirus containment effort.”

The Coronavirus Biochip tests simultaneously for Coronavirus SARS-CoV-2 (COVID-19), Sarbecoviris (SARS, SARS like, COVID-19), Coronavirus 229E/NL63, Coronavirus OC43/HKUI, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Adenovirus A/B/C/D/E, Enterovirus A/B/C, Influenza A, Influenza B and Rhinovirus A/B.

The Randox Coronavirus Biochip complies with guidelines from the Centres for Disease Control and Prevention and the World Health Organisation.

For more information or to arrange interviews, please contact the Randox PR team on 028 9442 2413 or email randoxpr@randox.com

 

QNOSTICS

QCMD

BIOSCIENCES


The use of antibiotics in the dairy industry

randox-food-diagnostics

About RFD        News        Contact Us

27 February 2020

The use of antibiotics in the dairy industry

 

The use of antibiotics in the dairy industry

In this month’s Randox Food Diagnostics blog, we look at the dairy industry and their use of antibiotics.

Antibiotics are used in the dairy industry routinely for pure preventative purposes. Due to poor conditions and hygiene, it is common that cattle will become infected which results in loss of milk yield and beef. Antibiotics are used to alleviate and prevent further suffering from potential zoonotic diseases.

Antibiotics are administered to cattle through a blanket use practice, within a herd to ensure all are treated. Once administered to the animal they must be given a ‘dry’ period when the dairy cattle are allowed to rest between lactations. This lasts roughly around 60 days in which a herd cannot be milked to ensure the antibiotics are out of the cattle’s milk. This however is at a cost to the farmer and cattle cannot be rushed back into milking too soon after administration.

To support the global dairy industry, and to help dairy processors monitor their use of antibiotics, Randox Food have developed the most comprehensive testing methods for milk.

The InfiniPlex for Milk Array is the world’s first screening technology that allows users to test for 130+ contaminants in milk in under 22 minutes. In addition to testing for antibiotics, InfiniPlex can detect anti-parasitic, non-steroidal, anti-inflammatory and anti-parasitic drug residues from a single sample using patented Biochip Array Technology.

Available on both the Evidence Investigator, a semi-automated system, capable of analysing up to 48 samples in under 2 hours and the Evidence MultiSTAT, a fully automated system that delivers results from a single neat sample of milk in under 22 minutes.

If you are a centralised laboratory, internal surveillance programme, low throughput laboratory or a dairy processor we have the perfect solution for your testing needs.

For more information on the antibiotic screening arrays available, contact info@randoxfooddiagnostics.com to find out how Randox Food can simplify your screening practices today.

Want to know more?

Contact us or visit our Randox Food Diagnostics website.

Related Products

Meat & Seafood

Milk

Honey

Wine


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×